Currently, the company has seven products in its research pipeline, including the targeted anti-tumor
drug max-4 project, which has got the us FDA orphan drug qualification in 2018, and launched the
clinical phase I trial of acute myeloid leukemia in both Australia and China.Based on the new targets
and mechanisms found in the China and Australia phase I clinical study, phase I clinical trial of solid
tumor was launched in China in 2019, and was awarded the "Major New Drug Creation" project of the
country major science and technology special project in the same year.
Another important project is the oral cancer immunotherapy drug max-1, which launched a phase I clinical
trial in Australia in 2019. The main preclinical studies of the project included a comparison of
head-to-head tumor inhibition rates with pd-l1 antibody Durvalumab and pd-1 antibody Pembrolizumab. And
in antibody-sensitive tumor models，thay are showing similar efficacy with antibody drugs. In the tumor
model with antibody sensitivity, the efficacy is superior to that of antibody drugs. The results
indicate that the antitumor spectrum is expected to be much wider than that of antibody drugs.